Apimeds Pharmaceuticals US (APUS) Non Operating Income (2024 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Non Operating Income came in at $5.9 million in Q4 2025, up 16437.48% YoY from N/an in Q4 2024, and up 9243.26% on a QoQ basis from $62984.0 in Q3 2025.
Apimeds Pharmaceuticals US (APUS) Non Operating Income (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 2 years of Non Operating Income data on file, last reported at $5.9 million in Q4 2025.
- Quarterly Non Operating Income rose 16437.48% year-over-year to $5.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.9 million (up 5245.07% YoY) and the FY2025 annual result came in at $5.9 million, up 5245.07% from the prior year.
- Non Operating Income climbed to $5.9 million in Q4 2025, from $62984.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $5.9 million in Q4 2025 to a low of -$38029.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | -224.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 5.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 41.90 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 10.70 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Apimeds Pharmaceuticals US | 7.35 Mn | 7.35 Mn | - | -13.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.88 Mn |
| Sep 30, 2025 | 62,984.00 |
| Jun 30, 2025 | 1,711.00 |
| Mar 31, 2025 | -38,029.00 |
| Dec 31, 2024 | -36,020.00 |
| Sep 30, 2024 | -32,522.00 |
| Jun 30, 2024 | -21,606.00 |
| Mar 31, 2024 | -24,747.00 |